Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $19.2700 (1.9%) ($19.2700 - $19.2700) on Mon. Feb. 1, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.22% (three month average) | RSI | 28 | Latest Price | $19.2700(1.9%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -1.1% a day on average for past five trading days. | Weekly Trend | FOLD declines -8% a week on average for past two weeks. | Market Behavior | Broad based rally for large cap. Broad based rally for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(49%) XBI(48%) IWM(46%) IWC(43%) | Factors Impacting FOLD price | FOLD will decline at least -1.61% in a week (0% probabilities). VIXM(-28%) VXX(-13%) UUP(-11%) UNG(-6%) USO(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.61% (StdDev 3.22%) | Hourly BBV | -0.2 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $5.97(-69.02%) | Inflection Point | Yes | Resistance Level | $21.35 | 5 Day Moving Average | $19.24(0.16%) | 10 Day Moving Average | $20.02(-3.75%) | 20 Day Moving Average | $21.35(-9.74%) | To recent high | -22.6% | To recent low | 8.7% | Market Cap | $4.976b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |